(Q37945308)

25 August 2017

Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450. (English)

1 reference

25 August 2017

0 references

1 reference

Paul O Gubbins

1

1 reference

PubMed ID

21995615

25 August 2017

language of work or name

English

0 references

publication date

13 October 2011

1 reference

Expert Opinion on Drug Metabolism & Toxicology

25 August 2017

1 reference

25 August 2017

7

1 reference

25 August 2017

11

1 reference

25 August 2017

1411-1429

1 reference

Clinically relevant drug interactions of current antifungal agents

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Cytochrome p450 and chemical toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Drug-drug interactions of antifungal agents and implications for patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Significance of the minor cytochrome P450 3A isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Cytochrome P450 3A: ontogeny and drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Role of itraconazole metabolites in CYP3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Polymorphism of human cytochrome P450 enzymes and its clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Optimisation of itraconazole therapy using target drug concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Stereochemical aspects of itraconazole metabolism in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Disposition of posaconazole following single-dose oral administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Voriconazole and fluconazole increase the exposure to oral diazepam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Absence of significant interaction of fluconazole with cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Interaction between voriconazole and tacrolimus in a kidney-transplanted patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Fluconazole-sirolimus drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

The effect of fluconazole on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Simvastatin-fluconazole causing rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Rhabdomyolysis in a patient receiving atorvastatin and fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of itraconazole on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Induction of fluconazole metabolism by rifampin: in vivo study in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Voriconazole: in the treatment of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Itraconazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

Effect of fluconazole on plasma fluvastatin and pravastatin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.627854

10.1517/17425255.2011.627854

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21995615